share_log

Reported Monday, Daiichi Sankyo And AstraZeneca's Datopotamab Deruxtecan Show Survival Improvement Versus Chemotherapy In Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer In TROPION-Lung01 Phase 3 Trial

Benzinga ·  May 28 03:03
  • In the overall trial population, survival results numerically favored Daiichi Sankyo and AstraZeneca's datopotamab deruxtecan but did not reach statistical significance
  • TROPION-Lung01 previously met the dual primary endpoint of progression-free survival in the overall trial population
  • Results support applications currently under review by regulatory authorities globally including the U.S. and EU
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment